Fujifilm Corporation

Fujifilm Corporation

Fujifilm Corporation was founded in 1934 as a photographic film manufacturer and spent most of the 20th century locked in a global duopoly with Eastman Kodak. When digital photography erased that market almost overnight, the company did not cling to its legacy business. Instead, it invested heavily in the chemistry, nanotechnology, and precision engineering it had developed for film and redirected those capabilities into cosmetics, pharmaceuticals, medical imaging, and high-performance materials. The pivot was orchestrated by then-CEO Shigetaka Komori and has become a canonical case study in surviving technological obsolescence. The company now operates across three core segments: Healthcare, Materials, and Imaging. Healthcare is the largest and most strategically important, anchored by Fujifilm's medical imaging systems, biopharmaceutical contract development and manufacturing (CDMO) services, and regenerative medicine research. In 2021, the firm committed $2 billion to build a large-scale CDMO facility in Holly Springs, North Carolina, directly competing with Lonza and Samsung Biologics for mammalian cell culture capacity. The Materials segment supplies advanced films, display materials, and semiconductor process chemicals — a business that has benefited from semiconductor fab expansion in the US and Japan. The legacy Imaging division still produces Instax instant cameras and digital printing systems but contributes a shrinking share of total revenue. Fujifilm employs roughly 73,000 people globally with significant operational footprints in North America, Europe, and Asia. In the United States, key hubs include Boston (healthcare R&D), Pasadena (cellular therapeutics), and Billerica (industrial products). The company does not disclose a consolidated alternative-investment pool, but its corporate venture arm, Fujifilm Corporation, invests directly in startup technologies adjacent to its strategic priorities. In May 2024, Fujifilm completed its acquisition of Atara Biotherapeutics' CAR-T manufacturing facility in Thousand Oaks, California, further expanding its cell-therapy CDMO footprint. Fujifilm also owns a 75% stake in Fujifilm Diosynth Biotechnologies, its biopharma CDMO subsidiary. The structural differentiator that sets Fujifilm apart from other diversified Japanese conglomerates is the depth of its organic transformation. Rather than outsourcing a venture strategy or acquiring growth at peak multiples, the company systematically redeployed its core materials science expertise into adjacent industries where those capabilities created genuine moats. The result is a business portfolio that looks nothing like its 1990s self yet required no crisis-era breakup or state rescue — a model of internal capital reallocation that remains rare among large-cap industrial firms.